Alison Long
Director/Board Member presso TAYSHA GENE THERAPIES, INC.
Patrimonio netto: - $ in data 31/03/2024
Profilo
Alison Long is currently a Director at Taysha Gene Therapies, Inc. She was previously the Chief Medical Officer at Kaleido Biosciences, Inc. and the Chief Medical Officer & Senior Vice President at Freeline Therapeutics Holdings Plc.
Dr. Long holds a doctorate degree from George Mason University and the University of the Witwatersrand.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 01/11/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Posizioni attive di Alison Long
| Società | Posizione | Inizio |
|---|---|---|
| TAYSHA GENE THERAPIES, INC. | Director/Board Member | 01/11/2023 |
Precedenti posizioni note di Alison Long
| Società | Posizione | Fine |
|---|---|---|
| KALEIDO BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 01/06/2022 |
| FREELINE THERAPEUTICS HOLDINGS PLC | Chief Tech/Sci/R&D Officer | 01/11/2021 |
Formazione di Alison Long
| George Mason University | Doctorate Degree |
| University of the Witwatersrand | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| KALEIDO BIOSCIENCES, INC. | Health Technology |
| TAYSHA GENE THERAPIES, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Freeline Therapeutics Holdings Plc
 Freeline Therapeutics Holdings Plc BiotechnologyHealth Technology Freeline Therapeutics Holdings Plc engages in the business of developing and commercializing gene therapies. It also develops gene therapies for bleeding and other debilitating disorders. The company was founded by Markus Hörer and Amit Chunilal Nathwani in 2015 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- Alison Long
